BioLineRx Ltd. Files 6-K Report
Ticker: BLRX · Form: 6-K · Filed: Jan 17, 2025 · CIK: 1498403
Sentiment: neutral
Topics: sec-filing, form-6k, press-release
TL;DR
BioLineRx filed a 6-K on Jan 17, 2025, with a press release attached. Check Exhibit 1 for details.
AI Summary
On January 17, 2025, BioLineRx Ltd. filed a Form 6-K to report the issuance of a press release. This filing incorporates by reference the press release as Exhibit 1, which is intended to be included in all effective registration statements filed by the company.
Why It Matters
This filing indicates that BioLineRx Ltd. has issued a press release and is making it available to the SEC, which could contain material updates for investors.
Risk Assessment
Risk Level: low — This is a routine filing to report the issuance of a press release, with no immediate financial or operational changes disclosed.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- January 17, 2025 (date) — Filing date and press release issuance date
- 001-35223 (company) — SEC file number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report the issuance of a press release by BioLineRx Ltd. on January 17, 2025, and to incorporate that press release as Exhibit 1.
When was this Form 6-K filed?
This Form 6-K was filed on January 17, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Does BioLineRx Ltd. file annual reports under Form 20-F or Form 40-F?
BioLineRx Ltd. files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
What is the SEC file number for BioLineRx Ltd.?
The SEC file number for BioLineRx Ltd. is 001-35223.
Filing Stats: 186 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-01-17 07:09:46
Filing Documents
- zk2532569.htm (6-K) — 8KB
- exhibit_1.htm (EX-99) — 14KB
- image0.jpg (GRAPHIC) — 27KB
- 0001178913-25-000145.txt ( ) — 61KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On January 17, 2025, the Registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. The first two paragraphs of the press release attached to this Form 6-K as Exhibit 1 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: January 17, 2025